TO THE EDITOR:
Case isolation has been the method of choice for dealing with disease epidemics for hundreds of years. Yamin and colleagues (1) improve on our knowledge of how to truncate the human-human transmission of a communicable disease by estimating the time during which case isolation is most effective for patients with Ebola, namely, within 4 days of symptom onset. Because rapidly fatal diseases for which no effective treatment is available tend to be self-limiting, can the authors estimate how long the Ebola pandemic will continue before it dies out on its own? 
IN RESPONSE:
The Ebola outbreak that swept across West Africa has been unprecedentedly devastating, yet recently showed encouraging signs for containment in Liberia (1) . In our study, we integrated data on daily viral load and contact patterns of patients with Ebola to evaluate the effectiveness of nonpharmaceutical interventions to curtail transmission in Liberia. We modeled transmission by considering 3 potential transmission routes: sharing a bed, a meal, and a conversation.
Our findings suggest that viral load had a greater effect on the probability of transmission from less intimate forms of contact where aerosol transmission is conceivable, such as sharing a conversation, than from more intimate forms of contact, such as sharing a bed. Consequently, even if aerosol transmission were possible, as Drs. Mohapatra and Mishra suggest, our main results would be even more robust. Specifically, nonsurvivors have a higher viral load, particularly after 4 days from symptoms onset. Thus, nonsurvivors cause more transmission than survivors, making early isolation of the most severely ill patients paramount to reducing household and community transmission.
Despite the exponential epidemiologic trajectory in Liberia during our study, we showed that targeting persons in critical condition within 4 days had a high probability of eliminating Ebola in Liberia. Furthermore, this intervention effort is logistically feasible, particularly because contact tracing has improved and Ebola treatment units have scaled up in recent months (2) . We have now extended our analysis to predict when Ebola could have been eliminated in Montserrado County and the expected number of cases if various isolation strategies had been initiated on 17 September 2014, the last data point of our previous study.
If all nonsurvivors could be isolated on the fourth day of symptoms, the median time to elimination in Montserrado County would be 162 days (interquartile range [IQR] , 119 to 281 days) and the median number of total cases would be 1657 (IQR, 1471 to 2142). If all nonsurvivors could be isolated on the third day after symptom onset, the median time for elimination would decrease to only 90 days (IQR, 65 to 138 days) with a median number of total cases of 1352 (IQR, 1278 to 1522) from the point of implementation. Conversely, if only 75% of nonsurvivors could be targeted on the fourth day of symptoms, the probability for elimination would be 74% with a median elimination time of 378 days and an epidemic magnitude of 2791 cases. These findings highlight the importance of exhaustive efforts to trace contacts and of educational campaigns to maintain awareness about Ebola symptoms and encourage symptomatic persons to seek health care until the Ebola outbreak is finally eliminated. Risk and diagnostic predictions differ in their targets, degrees of predictive accuracy, and time intervals. In diagnostic predictions, we wish to predict whether a person has detectable disease, the disease's time interval is instantaneous, and the prediction must be nearly 100% accurate. In risk predictions, we wish to predict the probability that a person will have detectable disease over a specified time interval and the prediction must be less than 100% accurate. These predictions differ greatly, and the distinction between risk and diagnosis is important for reporting prediction studies.
Dan
We pose 3 additional points. First, the authors do not mention the problem of "lifetime" predictions. Second, they state, "In case of poor performance, the model can be updated or adjusted on the basis of the validation data set." However, they do not say that the updating or adjustment means that the investigators have looked at their results, which indicates that they must do another, independent external validation study. Finally, because most of the medical prediction literature currently consists of bivariate studies (4) 
IN RESPONSE:
The Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) Statement concerns prediction models that are developed for diagnosis or prognosis. We believe that the additional type of prediction that Dr. Burke refers to as "risk prediction" is subsumed within the prognostic framework. Prognostic models as referred to in TRIPOD predict a certain health condition (such as death, a disease, a complication, a recurrent event, or any other outcome) over a specified period in participants at risk for this condition. Therefore, prognostic models may address ill or healthy persons, such as by predicting the 1-year probability of dying for a patient with lung cancer or the long-term (for example, 10-year) probability of cardiovascular disease for a healthy person.
As Dr. Burke correctly points out, we did not explicitly mention the issues of models for predicting lifetime risk. How-ever, studies of this type of prediction model fit entirely within the remit of TRIPOD. We decided not to explicitly discuss these issues because a model for predicting lifetime risk is unlikely to be developed. If interest in these models increases, these issues will undoubtedly be explicitly mentioned when TRIPOD is revised and updated. However, as previously discussed, we believe that these models are just examples of models predicting long-term outcomes in (healthy) general populations.
We completely agree that any updated model should be further evaluated in a separate data set. In our accompanying article, we stress that "The updated model is in essence a new model. . . . Updated models, certainly when based on relatively small validation sets, still need to be validated before application in routine practice" (1) .
Dr. Burke's final comment concerns single-marker (biomarkers and prognostic factors) studies. Although multivariable prediction model studies and single-marker studies that apply some form of multivariable analysis are clearly similar, the differences are noticeable. That such multivariable analysis is being applied does not necessarily make it a prediction model study. The delineating factor is that one develops, validates, or updates a multivariable prediction model that, as such, can be used to produce a probability (or risk) estimate for a person. In other words, TRIPOD addresses models that allow for individualized predictions. "Individualized" can be considered the most important word in the TRIPOD acronym. For studies of single markers, authors should ensure complete and accurate reporting following the reporting recommendations for tumor marker prognostic studies guideline (2) .
Screening for Vitamin D Deficiency
TO THE EDITOR: We read LeBlanc and colleagues' review (1) with great interest. Approximately twice as many metaanalyses have been done on vitamin D supplements for falls and fractures as randomized trials. Conclusions of these meta-analyses differ largely because of the methods adopted, such as the choice of studies included (2, 3) . LeBlanc and colleagues assessed the effectiveness of vitamin D supplementation on mortality, falls, and fractures in vitamin D deficiency, including 11, 5, and 5 trials, respectively, for each outcome. In contrast, we included 38, 20, and 23 trials, respectively, in meta-analyses of vitamin D supplementation for these conditions (4, 5) . The differences in study inclusion are largely due to LeBlanc and colleagues' requirement that baseline 25-hydroxyvitamin D [25-(OH)D] levels be measured in all participants. They aimed to include only studies in which 90% of participants had 25-(OH)D levels less than 75 nmol/L, but random sampling of baseline levels is sufficient to assess this criterion. Baseline 25-(OH)D levels were reported in a sample or in all participants in most (34 of 42) trials in our meta-analyses, with 25 of 32 (78%) reporting mean baseline 25-(OH)D levels less than 50 nmol/L; thus, 90% of participants most likely had 25-(OH)D levels less than 75 nmol/L.
Inconsistency in study and participant inclusion is an additional consequence of LeBlanc and colleagues' methods. Of 2 studies done by the same investigators in the same population group, 1 was included in which 25-(OH)D levels were measured in all participants; the other was excluded because these levels were measured in only a subset of participants even though mean baseline 25-(OH)D levels were similar in the 2 studies. Likewise, a small subset of participants in 2 studies was included in this meta-analysis because they were selected to have baseline 25-(OH)D levels measured, whereas most participants in both studies were excluded.
The upshot is that LeBlanc and colleagues' meta-analyses contain few events and participants and do not include most studies with fracture or falls as the primary end point. Previous reviews on vitamin D for the U.S. Preventive Services Task Force also have not included eligible studies. Consequently, conclusions based on these reviews may not be reliable. Research resources are finite in these times of austerity; hence, they should be allocated appropriately. Robust and pertinent evidence is needed to formulate educational and interventional policies that can be implemented to prevent the global public health problem of cardiometabolic diseases and autoimmune and neoplastic conditions associated with decreased bioavailable concentrations of vitamin D. TO THE EDITOR: LeBlanc and colleagues (1) conclude that treatment of vitamin D deficiency in asymptomatic adults might reduce the risk for falls but not fractures. This conclusion requires an explanation, because a fall is one of the strongest risk factors for a fracture. We present an evidence-based, mechanistic insight into this unexpected result.
Muscle force is related to bone strength, and the risk reduction of falls but not fractures (1) theoretically means that treatment of vitamin D deficiency reduces fall risk by improving balance (rather than muscle force) but does not change fracture risk by impairing bone strength. The former would be consistent with clinical evidence, whereas the latter could be associated with skeletal adaptation to the mechanical environment (2) (3) (4) (5) . Bone begins to deform plastically at a yield force, and normal physical activity causes the preyield "elastic" deformation (strain) of bone. A decrease in bone quality associated with minerals induces an increase in the "elastic" deformation, whereas the skeleton responds to the mechanical environment to maintain the resultant strain of bone. Consequently, mineral-related impairment of bone quality can be compensated by mechanical strain-related feedback control and might decrease bone fragility if compensated efficiently (3). For example, patients with hypophosphatemic rickets or osteomalacia have a lower quality and higher quantity of bone (2) . Vitamin D deficiency impairs bone quality, and children with nutritional rickets would also have bigger, long bones (4). Furthermore, a recent study in children with cerebral palsy showed an inverse correlation between serum levels of 25-(OH)D and Z scores for areal bone mineral density in the distal femur (4). Of note, the latest meta-analysis in adults found that supplementation with at least 800 IU/d of vitamin D has fewer effects on areal bone mineral density than supplementation with less than 800 IU/d of vitamin D in the lumbar spine and potentially the femoral neck but not the forearm (5).
Finally, many observational studies have shown an association between lower levels of 25-(OH)D and higher incidences of fracture in adults. However, LeBlanc and colleagues' conclusion suggests that confounding biases the association. Vitamin D status is strongly influenced by sunlight exposure associated with outdoor activity, whereas mechanical loading from habitual physical activity is the primary determinant of bone strength. These factors imply that higher incidences of fracture could result from lower levels of physical activity rather than of 25-(OH)D.
Toshihiro Sugiyama, MD, PhD Yoon Taek Kim, MD, PhD Hiromi Oda, MD, PhD
Saitama Medical University Saitama, Japan
IN RESPONSE:
The purpose of our systematic review was to determine whether screening for vitamin D deficiency in asymptomatic persons improved health outcomes. Therefore, we determined a priori that we would include only studies of populations that had documented vitamin D deficiency and were not selected on the basis of a history of osteoporosis, prior fractures, or falls. Thus, we included fewer studies than the meta-analyses by Dr. Bolland and colleagues (1, 2), which also included trials of participants with normal vitamin D levels and with osteoporosis and prior fractures or falls. We did not exclude any study solely because only a random sample of the population had vitamin D deficiency according to our definition [90% of persons with 25-(OH)D levels <75 nmol/L]. Either the subsample did not meet this deficiency definition or the study was excluded because of another reason (for example, patients had prior fractures or falls). In the specific example mentioned by Dr. Bolland and colleagues (3, 4) , the study of the subsample of participants was excluded because the subsample population did not meet our criterion for deficiency; however, the overall trial was included because when 25-(OH)D levels were measured in all participants, more than 90% were deficient. Although some of our analyses had relatively few events, expanding inclusion to clinically heterogeneous populations that are not of interest in order to increase statistical power would not have been appropriate.
We agree with Dr. Kain that research on the role of bioavailable vitamin D levels is important to better understand the effects of vitamin D treatment on clinical outcomes. We also agree with Dr. Sugiyama and associates that research is needed on mechanisms for how vitamin D might prevent falls but not fracture.
In response to Heaney and Armas' editorial (5), we explicitly defined the scope of the review before starting the work. We addressed the factors raised in the editorial as potentially affecting estimates in sensitivity and stratified analyses. Further stratifying or restricting the analysis, as Heaney and Armas suggested, would result only in even less evidence to support the benefits of vitamin D treatment. It is important to understand that the function of vitamin D and the other micronutrients is facilitative. They are necessary for cell function but not causative thereof. In the absence of physiologic need, they do nothing, and increasing their intake has no proper effect. The definition of adequacy for all the micronutrients should not be the absence of some disease (rickets, beriberi, and scurvy) but the optimal functioning of all body systems. The need varies by system; it is relatively high for lactation (>112 nmol/L) and somewhat less so for optimal skeletal mineralization (>75 nmol/L). However, the requirement for the whole organism is the intake that supports all physiologic functioning. Because response to dosing varies widely (with a coefficient of variation of nearly 40%), we can be assured that we have achieved the proper level only by measuring serum 25-(OH)D concentrations. 
Erin S. LeBlanc, MD, MPH

TO THE EDITOR:
